BRIVIACT

Post-LOE

brivaracetam

NDAINTRAVENOUSSOLUTION
Approved
Feb 2016
Lifecycle
Post-LOE
Competitive Pressure
35/100
Clinical Trials
20

Mechanism of Action

Epoxide Hydrolase Inhibitors

Clinical Trials (5)

NCT06315322Phase 3Recruiting

A Study to Test the Long-term Safety and Tolerability of Brivaracetam in Study Participants With Childhood Absence Epilepsy or Juvenile Absence Epilepsy

Started Jul 2024
120 enrolled
Childhood Absence EpilepsyJuvenile Absence Epilepsy
NCT06312566Phase 1Completed

A Study to Assess the Bioequivalence Between Brivaracetam Tablet and Dry Syrup in Healthy Japanese Male Study Participants

Started Mar 2024
64 enrolled
Healthy Study Participants
NCT05315947Phase 1Completed

A Study to Assess the Bioequivalence Between Brivaracetam Tablet and Dry Syrup in Healthy Male Japanese Study Participants

Started Apr 2022
24 enrolled
Healthy Study Participants
NCT05109234Phase 3Completed

A Study to Test the Long-term Safety, Tolerability and Efficacy of Brivaracetam in Study Participants 2 to 26 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy

Started Mar 2022
84 enrolled
Childhood Absence EpilepsyJuvenile Absence Epilepsy
NCT04666610Phase 3Active Not Recruiting

A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy

Started Jul 2021
153 enrolled
Childhood Absence EpilepsyJuvenile Absence Epilepsy

Loss of Exclusivity

LOE Date
Feb 21, 2026
1 months ago
Patent Expiry
Feb 21, 2026

Patent Records (1)

Patent #ExpiryTypeUse Code
6911461
Feb 21, 2026Expired
SubstanceProduct
U-2130